Shares of Cocrystal Pharma, Inc. (NASDAQ:COCP – Get Rating) rose 1.3% on Wednesday . The stock traded as high as $2.40 and last traded at $2.35. Approximately 36,861 shares changed hands during mid-day trading, a decline of 42% from the average daily volume of 63,915 shares. The stock had previously closed at $2.32.
Analyst Upgrades and Downgrades
Separately, HC Wainwright raised their price objective on Cocrystal Pharma to $42.00 and gave the stock a “buy” rating in a research report on Monday, November 7th.
Cocrystal Pharma Price Performance
The company’s 50-day moving average price is $2.43 and its two-hundred day moving average price is $3.48. The company has a market capitalization of $19.08 million, a price-to-earnings ratio of -0.50 and a beta of 1.04.
About Cocrystal Pharma
Cocrystal Pharma, Inc, a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections.
Featured Stories
- Get a free copy of the StockNews.com research report on Cocrystal Pharma (COCP)
- Procter & Gamble Earnings: A Gamble Worth Taking
- Stocks Slide, Economic Report Paints Gloomy Picture For Economy
- What does Nu Holdings Stock Have To Do With Warren Buffett?
- J.B. Hunt Gets A Flat, Logistic Companies Come Into Focus
- Is Intel Stock On The Verge Of Breaking Out?
Receive News & Ratings for Cocrystal Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cocrystal Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
